Navigation Links
Cell Therapeutics to Exchange up to $89.2 million of Its Outstanding Convertible Notes in a 'Modified Dutch Auction' Tender Offer
Date:5/12/2009

ion will consist of (i) $200 in cash, and (ii) a number of shares of Common Stock with a value equal to the Exchange Consideration minus $200 (the "Common Stock Portion", and such number of shares of our Common Stock being the "Common Stock Consideration"). The number of shares of Common Stock received by holders as part of the Exchange Consideration will equal the quotient obtained by dividing (x) the Common Stock Portion by (y) the average of the daily volume weighted average price of the Common Stock on the national securities exchange on which the Common Stock is listed or quoted for trading as reported by Bloomberg L.P. (based on a trading day from 9:30 a.m. (New York City time) to 4:02 p.m. (New York City time)) for the 10 trading days from and including May 19, 2009 to and including June 2, 2009 (the "10-day VWAP"). The Company will announce the 10-day VWAP prior to the opening of trading on June 3, 2009. Accrued and unpaid interest on Notes validly tendered and not withdrawn, up to, but not including, the date of exchange, will be exchanged for that number of shares of Common Stock determined by dividing (1) the amount of accrued and unpaid interest on a Note, by (2) the 10-day VWAP, and as further described herein. However, in no event will the aggregate number of shares of Common Stock Consideration plus the aggregate number of shares of Common Stock to be exchanged for accrued and unpaid interest exceed a maximum number of shares of our Common Stock (the "Common Stock Limit") to be disclosed in the Schedule TO (including the Offer to Exchange and related Letter of Transmittal) that will be filed by the Company with the Securities and Exchange Commission ("SEC"). In the event the aggregate number of shares of Common Stock Consideration plus the aggregate number of shares of Common Stock to be exchanged for accrued and unpaid interest exceeds the Common Stock Limit, the Company will terminate the Exchange Offer.

The description of the Ex
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. PTC Therapeutics and Spinal Muscular Atrophy Foundation Announce $8.5 Million Small Molecule Development Collaboration
2. Orexigen(R) Therapeutics Announces Jay Hagan as Senior Vice President, Corporate Development and Strategy
3. Amicus Therapeutics to Present at the Bank of America and Merrill Lynch 2009 Health Care Conference on May 13, 2009
4. Orexigen(R) Therapeutics to Speak at Upcoming Conferences
5. Orexigen(R) Therapeutics Announces First Quarter 2009 Financial Results
6. Nektar Therapeutics Reports First Quarter 2009 Financial Results
7. Cell Therapeutics, Inc. (CTI) to Report 2009 First Quarter Financial Results on May 7
8. Arno Therapeutics to Deregister its Common Stock under the Exchange Act
9. TorreyPines Therapeutics Reports First Quarter 2009 Financial Results
10. United Therapeutics Reports First Quarter 2009 Financial Results
11. Amicus Therapeutics Announces First Quarter 2009 Financial Results Release Date
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/1/2015)... MN , May 1, 2015 /PRNewswire/ - BioAmber ... producing sustainable chemicals, today announced that it has priced an ... stock at a price of $9.00 per share, and ... to purchase up to an additional 585,000 shares of ... will be $35.1 million.  The offering is expected to close ...
(Date:5/1/2015)... , May 1, 2015 ... Genetic Technologies Ltd (NASDAQ: GENE ), Agilent ... Scientific Inc. (NYSE: TMO ), Sequenom Inc. ... PKI ). Free research report on Genetic ... On Thursday, April 30, 2015, the NASDAQ Composite ...
(Date:4/30/2015)... Blythewood, South Carolina (PRWEB) May 01, 2015 ... steam system services, is extremely proud to announce that ... have been named as a winner of a Queen’s ... business success for the design and manufacture of a ... is the revolutionary alternative to traditional steam flow ...
(Date:4/30/2015)... - BioAmber Inc. (NYSE: BIOA ), an industrial ... commenced an underwritten public offering of its common stock.  ... 30-day option to purchase up to an additional 15 ... the public offering. The offering is subject to market ... whether or when the offering may be completed, or ...
Breaking Biology Technology:BioAmber Inc. Announces Pricing Of $35.1 Million Registered Offering 2BioAmber Inc. Announces Pricing Of $35.1 Million Registered Offering 3Life Sciences Tools and Services Stocks on our Radar -- Genetic Technologies, Agilent Technologies, Thermo Fisher Scientific, Sequenom, and PerkinElmer 2Life Sciences Tools and Services Stocks on our Radar -- Genetic Technologies, Agilent Technologies, Thermo Fisher Scientific, Sequenom, and PerkinElmer 3Life Sciences Tools and Services Stocks on our Radar -- Genetic Technologies, Agilent Technologies, Thermo Fisher Scientific, Sequenom, and PerkinElmer 4Life Sciences Tools and Services Stocks on our Radar -- Genetic Technologies, Agilent Technologies, Thermo Fisher Scientific, Sequenom, and PerkinElmer 5Spirax Sarco Receives a Queen’s Award for Innovation 2Spirax Sarco Receives a Queen’s Award for Innovation 3BioAmber Inc. Announces Public Offering Of Common Stock 2BioAmber Inc. Announces Public Offering Of Common Stock 3
... Multiple Fields, Strengthening the Molecular Bioassays Market , ... Based on its recent analysis of the molecular ... with the 2009 Frost & Sullivan North America ... pioneering Tag-lite(TM) technology for cell surface receptor investigation, ...
... , PHILADELPHIA and LONDON, June 9 /PRNewswire/ -- ... reported today that, despite difficult economic times, renewals of ... many existing customers have even added new content to ... is the world,s largest citation database, providing researchers, administrators, ...
... Executive to Lead Personalized Medicine Company in Next Phase of Growth ... , a personalized medicine company, announced today ... new President and CEO. , , Burns comes to ... strategic management of science and technology for pharmaceutical, diagnostic, and biotech ...
Cached Biology Technology:Frost & Sullivan Recognizes Cisbio Bioassays for Technology Innovation 2Frost & Sullivan Recognizes Cisbio Bioassays for Technology Innovation 3Frost & Sullivan Recognizes Cisbio Bioassays for Technology Innovation 4Frost & Sullivan Recognizes Cisbio Bioassays for Technology Innovation 5Web of Science(R) Renewals Remain Strong Despite Tough Economic Climate 2AssureRx Adds New CEO 2
(Date:3/31/2015)...   Guidepoint , a leading global research services ... Management TRACKER, part of the Guidepoint TRACKER ... medical device and therapeutics markets. The Post-Surgical Pain Management ... market share, and adoption rates across three major modalities ... The Post-Surgical Pain Management TRACKER will provide ...
(Date:3/24/2015)... and Markets ( http://www.researchandmarkets.com/research/hdgz7h/global_iris ) has announced ... 2015-2019" report to their offering. The ... at a CAGR of 23.5 percent over the period ... and the growth prospects of the Global Iris Recognition ... size, the report considers the revenue generated from sales ...
(Date:3/24/2015)... , March 24, 2015   Crossmatch ™, ... today announced that its U.are.U ® 4500 ... Goorin Bros . to achieve PCI compliance ... secures access to the POS terminal, protecting the ... of data breaches. With one-third ...
Breaking Biology News(10 mins):Guidepoint Launches Post-Surgical Pain Management TRACKER 2Guidepoint Launches Post-Surgical Pain Management TRACKER 3Global Iris Recognition Market 2015-2019 with 3M Cogent, Bioenable Technologies, Cross Match Technology, Iris ID Systems & Safran Dominating 2Crossmatch Fingerprint Readers Help Retailer Prevent Data Breaches at Point-of-Sale 2
... occur in sports and in combat, but health experts ... head movements during these activities pose the greatest risks ... have developed a powerful new computer-based process that helps ... injuries. This approach could lead to new medical treatment ...
... 12, 2013The foodborne bacteria Listeria monocytogenes sickens ... many more worldwide, killing about 25-30% of those infected. ... L. monocytogenes , and current methods for detecting the ... method for developing an inexpensive biosensor to detect the ...
... maxillary sinuses. Those bulbous pouches on either side of the ... sinus infections than anything else. They were thought to be ... present value. Yet researchers led by the University of ... role in the shape and function of the human nose, ...
Cached Biology News:Computer model may help athletes and soldiers avoid brain damage and concussions 2Computer model may help athletes and soldiers avoid brain damage and concussions 3Low-cost nano-biosensor to detect foodborne pathogen that causes listeriosis 2Low-cost nano-biosensor to detect foodborne pathogen that causes listeriosis 3The nose's unheralded neighbor 2The nose's unheralded neighbor 3